曲霉特异性IgG抗体诊断慢性肺曲霉病与参考标准的比较
本研究以组织学确诊的慢性肺曲霉病患者为参考标准,评估曲霉特异性IgG抗体的诊断性能。在丹麦、德国、比利时、印度、摩尔多瓦和巴基斯坦的合作站点收集47例组织学确诊患者,并在德国博尔斯特研究中心前瞻性收集303例患病与健康对照。ImmunoCAP®检测的敏感性为85.1%(95%CI:71.7-93.8%),特异性为83.6%(95%CI:78.0-88.3%);组织学确诊患者的中位滴度为83.45 mgA/L(四分位距38.9-115.5),显著高于其他所有队列(p < 0.001);79例健康对照中三分之一出现假阳性。
要点
- 以组织学确诊CPA为参考标准,ImmunoCAP®曲霉特异性IgG的敏感性为85.1%、特异性为83.6%。
- 组织学确诊CPA患者中位滴度83.45 mgA/L,显著高于其他所有队列(p < 0.001)。
- 79例健康对照中三分之一出现假阳性,阳性结果应始终结合影像学发现。
核心结论
- 研究结果证实曲霉特异性IgG抗体检测以组织学确诊CPA患者为参考标准时对CPA诊断具有高敏感性,但阳性结果应始终与影像学发现相符,因假阳性结果限制该检测的解读。
研究设计与样本
- 与CPAnet研究站点合作,从丹麦、德国、比利时、印度、摩尔多瓦和巴基斯坦收集组织学确诊慢性肺曲霉病患者(N = 47)的曲霉特异性IgG抗体滴度。
- 在德国博尔斯特研究中心内科前瞻性收集患病与健康对照的血清(n = 303)。
- 采用ImmunoCAP®检测(Phadia 100,Thermo Fisher Scientific,乌普萨拉,瑞典)测定曲霉特异性IgG抗体滴度,以≥50 mgA/L为阳性。
主要发现
- 以组织学确诊CPA患者为参考标准,ImmunoCAP®曲霉特异性IgG抗体检测的敏感性为85.1%(95% CI:71.7-93.8%),特异性为83.6%(95% CI:78.0-88.3%)。
- 组织学确诊CPA患者的中位曲霉特异性IgG抗体滴度为83.45 mgA/L(四分位距38.9-115.5),显著高于其他所有队列(p < 0.001)。
- 79例健康对照中三分之一出现假阳性检测结果。
关键数值与推荐
- 曲霉特异性IgG抗体滴度≥50 mgA/L视为阳性。
- 组织学确诊CPA患者为参考标准时,ImmunoCAP®检测敏感性85.1%(95% CI:71.7-93.8%)、特异性83.6%(95% CI:78.0-88.3%)。
临床怎么用
- 阳性检测结果应始终与影像学发现相符,因假阳性结果限制该检测的解读。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the performance of Aspergillus-specific IgG antibodies for diagnosing chronic pulmonary aspergillosis (CPA) by using a cohort of patients with histologically proven CPA as a reference standard. METHODS: We collected Aspergillus-specific IgG antibody titres from patients with histologically proven CPA in collaboration with CPAnet study sites in Denmark, Germany, Belgium, India, Moldova, and Pakistan (N = 47). Additionally, sera from diseased and healthy controls were prospectively collected at the Medical Clinic of the Research Center, Borstel, Germany (n = 303). Aspergillus-specific IgG antibody titres were measured by the ImmunoCAP® assay (Phadia 100, Thermo Fisher Scientific, Uppsala, Sweden). An Aspergillus-specific IgG antibody titre ≥50 mgA/L was considered positive. RESULTS: Using patients with histologically proven CPA as the reference standard, the ImmunoCAP® Aspergillus-specific IgG antibody test had a sensitivity and specificity of 85.1% (95% CI: 71.7-93.8%) and 83.6% (95% CI: 78.0-88.3%), respectively. Patients with histologically proven CPA had significantly higher Aspergillus-specific IgG antibody titre with a median of 83.45 mgA/L (interquartile range 38.9-115.5) than all other cohorts (p < 0.001). False-positive test results occurred in one-third of 79 healthy controls. DISCUSSION: Our study results confirm a high sensitivity of the Aspergillus-specific IgG antibody test for the diagnosis of CPA when using patients with histologically proven CPA as a reference standard. However, positive test results should always match radiological findings as false-positive test results limit the interpretation of the test.
引用
- Salzer HJF, Reimann M, Oertel C, et al. Aspergillus-specific IgG antibodies for diagnosing chronic pulmonary aspergillosis compared to the reference standard. Clin Microbiol Infect. 2023. PMID: 37689265. doi:10.1016/j.cmi.2023.08.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。